drugset / Trial / NCT01394991

A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia

NCT01394991

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the safety of epoetin alfa in patients with cancer who have chemotherapy-related anemia.

Timeline

Start
2006-01
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 150 iu/kg Subcutaneous
Subject epoetin alfa Protein / enzyme biologic 450 iu/kg Subcutaneous

Indications